AI assistant
BIOCRYST PHARMACEUTICALS INC — Director's Dealing 2017
Sep 5, 2017
31868_dirs_2017-09-05_25a49b0c-bfdb-40b7-b7b0-b160451003d9.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: BIOCRYST PHARMACEUTICALS INC (BCRX)
CIK: 0000882796
Period of Report: 2017-08-31
Reporting Person: STAAB THOMAS R II (Senior Vice President and CFO)
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2017-08-31 | Emp. Stock Option (Right to Buy) | $11.13 | A | 27000 | Acquired | 2024-12-22 | Common Stock (27000) | Direct |
Footnotes
F1: On August 30, 2017, the Science Committee of the Board of Directors determined that the BCX7353 APeX-1 clinical trial met its goals and BCX7353 warrants further development. As a result, on August 31, 2017, the Compensation Committee of the Board of Directors determined that one of the vesting criteria associated with the performance-based stock options awarded in December 2014 to all employees, excluding the Chief Executive Officer, has been met. Therefore, 30% of the performance-based stock options vested on August 31, 2017.